Table of Content - Neuropathic Pain Market Therapeutics & Growth Report 2032 | MRFR

Neuropathic Pain Market Segmentation

Neuropathic Pain Type Outlook (USD Billion, 2018-2030)

Painful Diabetic Peripheral Neuropathy

Autonomic Neuropathy

Focal Neuropathy

Proximal Neuropathy

Neuropathic Pain Indication Outlook (USD Billion, 2018-2030)

Diabetic Neuropathy

Spinal Stenosis

Chemotherapy Induced Peripheral Neuropathy

Neuropathic Pain Diagnosis Outlook (USD Billion, 2018-2030)

Imaging

Blood Tests and Physical Examination

Neuropathic Pain Treatment Outlook (USD Billion, 2018-2030)

Medications

Multimodal Therapy

Neuropathic Pain End User Outlook (USD Billion, 2018-2030)

Hospitals

Clinics

Research Organization

Neuropathic Pain Regional Outlook (USD Billion, 2018-2030)

North America Outlook (USD Billion, 2018-2030)
- North America Neuropathic Pain Type
  - Painful Diabetic Peripheral Neuropathy
  - Autonomic Neuropathy
  - Focal Neuropathy
  - Proximal Neuropathy
- North America Neuropathic Pain Indication
  - Diabetic Neuropathy
  - Spinal Stenosis
  - Chemotherapy Induced Peripheral Neuropathy
- North America Neuropathic Pain Diagnosis
  - Imaging
  - Blood Tests and Physical Examination
- North America Neuropathic Pain Treatment
  - Medications
  - Multimodal Therapy
- North America Neuropathic Pain End User
  - Hospitals
  - Clinics
  - Research Organization
- US Outlook (USD Billion, 2018-2030)
- US Neuropathic Pain Type
  - Painful Diabetic Peripheral Neuropathy
  - Autonomic Neuropathy
  - Focal Neuropathy
  - Proximal Neuropathy
- US Neuropathic Pain Indication
  - Diabetic Neuropathy
  - Spinal Stenosis
  - Chemotherapy Induced Peripheral Neuropathy
- US Neuropathic Pain Diagnosis
  - Imaging
  - Blood Tests and Physical Examination
- US Neuropathic Pain Treatment
  - Medications
  - Multimodal Therapy
- US Neuropathic Pain End User
  - Hospitals
  - Clinics
  - Research Organization
- CANADA Outlook (USD Billion, 2018-2030)
- CANADA Neuropathic Pain Type
  - Painful Diabetic Peripheral Neuropathy
  - Autonomic Neuropathy
  - Focal Neuropathy
  - Proximal Neuropathy
- CANADA Neuropathic Pain Indication
  - Diabetic Neuropathy
  - Spinal Stenosis
  - Chemotherapy Induced Peripheral Neuropathy
- CANADA Neuropathic Pain Diagnosis
  - Imaging
  - Blood Tests and Physical Examination
- CANADA Neuropathic Pain Treatment
  - Medications
  - Multimodal Therapy
- CANADA Neuropathic Pain End User
  - Hospitals
  - Clinics
  - Research Organization

Europe Outlook (USD Billion, 2018-2030)
- Europe Neuropathic Pain Type
  - Painful Diabetic Peripheral Neuropathy
  - Autonomic Neuropathy
  - Focal Neuropathy
  - Proximal Neuropathy
- Europe Neuropathic Pain Indication
  - Diabetic Neuropathy
  - Spinal Stenosis
  - Chemotherapy Induced Peripheral Neuropathy
- Europe Neuropathic Pain Diagnosis
  - Imaging
  - Blood Tests and Physical Examination
- Europe Neuropathic Pain Treatment
  - Medications
  - Multimodal Therapy
- Europe Neuropathic Pain End User
  - Hospitals
  - Clinics
  - Research Organization
- Germany Outlook (USD Billion, 2018-2030)
- Germany Neuropathic Pain Type
  - Painful Diabetic Peripheral Neuropathy
  - Autonomic Neuropathy
  - Focal Neuropathy
  - Proximal Neuropathy
- Germany Neuropathic Pain Indication
  - Diabetic Neuropathy
  - Spinal Stenosis
  - Chemotherapy Induced Peripheral Neuropathy
- Germany Neuropathic Pain Diagnosis
  - Imaging
  - Blood Tests and Physical Examination
- Germany Neuropathic Pain Treatment
  - Medications
  - Multimodal Therapy
- Germany Neuropathic Pain End User
  - Hospitals
  - Clinics
  - Research Organization
- France Outlook (USD Billion, 2018-2030)
- France Neuropathic Pain Type
  - Painful Diabetic Peripheral Neuropathy
  - Autonomic Neuropathy
  - Focal Neuropathy
  - Proximal Neuropathy
- France Neuropathic Pain Indication
  - Diabetic Neuropathy
  - Spinal Stenosis
  - Chemotherapy Induced Peripheral Neuropathy
- France Neuropathic Pain Diagnosis
  - Imaging
  - Blood Tests and Physical Examination
- France Neuropathic Pain Treatment
  - Medications
  - Multimodal Therapy
- France Neuropathic Pain End User
  - Hospitals
  - Clinics
  - Research Organization
- UK Outlook (USD Billion, 2018-2030)
- UK Neuropathic Pain Type
  - Painful Diabetic Peripheral Neuropathy
  - Autonomic Neuropathy
  - Focal Neuropathy
  - Proximal Neuropathy
- UK Neuropathic Pain Indication
  - Diabetic Neuropathy
  - Spinal Stenosis
  - Chemotherapy Induced Peripheral Neuropathy
- UK Neuropathic Pain Diagnosis
  - Imaging
  - Blood Tests and Physical Examination
- UK Neuropathic Pain Treatment
  - Medications
  - Multimodal Therapy
- UK Neuropathic Pain End User
  - Hospitals
  - Clinics
  - Research Organization
- ITALY Outlook (USD Billion, 2018-2030)
- ITALY Neuropathic Pain Type
  - Painful Diabetic Peripheral Neuropathy
  - Autonomic Neuropathy
  - Focal Neuropathy
  - Proximal Neuropathy
- ITALY Neuropathic Pain Indication
  - Diabetic Neuropathy
  - Spinal Stenosis
  - Chemotherapy Induced Peripheral Neuropathy
- ITALY Neuropathic Pain Diagnosis
  - Imaging
  - Blood Tests and Physical Examination
- ITALY Neuropathic Pain Treatment
  - Medications
  - Multimodal Therapy
- ITALY Neuropathic Pain End User
  - Hospitals
  - Clinics
  - Research Organization
- SPAIN Outlook (USD Billion, 2018-2030)
- SPAIN Neuropathic Pain Type
  - Painful Diabetic Peripheral Neuropathy
  - Autonomic Neuropathy
  - Focal Neuropathy
  - Proximal Neuropathy
- SPAIN Neuropathic Pain Indication
  - Diabetic Neuropathy
  - Spinal Stenosis
  - Chemotherapy Induced Peripheral Neuropathy
- SPAIN Neuropathic Pain Diagnosis
  - Imaging
  - Blood Tests and Physical Examination
  - SPAIN Neuropathic Pain Treatment
  - Medications
  - Multimodal Therapy
- SPAIN Neuropathic Pain End User
  - Hospitals
  - Clinics
  - Research Organization
- Rest Of Europe Outlook (USD Billion, 2018-2030)
- Rest Of Europe Neuropathic Pain Type
  - Painful Diabetic Peripheral Neuropathy
  - Autonomic Neuropathy
  - Focal Neuropathy
  - Proximal Neuropathy
- Rest Of Europe Neuropathic Pain Indication
  - Diabetic Neuropathy
  - Spinal Stenosis
  - Chemotherapy Induced Peripheral Neuropathy
- Rest Of Europe Neuropathic Pain Diagnosis
  - Imaging
  - Blood Tests and Physical Examination
- Rest Of Europe Neuropathic Pain Treatment
  - Medications
  - Multimodal Therapy
- Rest Of Europe Neuropathic Pain End User
  - Hospitals
  - Clinics
  - Research Organization

Asia-Pacific Outlook (USD Billion, 2018-2030)
- Asia-Pacific Neuropathic Pain Type
  - Painful Diabetic Peripheral Neuropathy
  - Autonomic Neuropathy
  - Focal Neuropathy
  - Proximal Neuropathy
- Asia-Pacific Neuropathic Pain Indication
  - Diabetic Neuropathy
  - Spinal Stenosis
  - Chemotherapy Induced Peripheral Neuropathy
- Asia-Pacific Neuropathic Pain Diagnosis
  - Imaging
  - Blood Tests and Physical Examination
- Asia-Pacific Neuropathic Pain Treatment
  - Medications
  - Multimodal Therapy
- Asia-Pacific Neuropathic Pain End User
  - Hospitals
  - Clinics
  - Research Organization
- China Outlook (USD Billion, 2018-2030)
- China Neuropathic Pain Type
  - Painful Diabetic Peripheral Neuropathy
  - Autonomic Neuropathy
  - Focal Neuropathy
  - Proximal Neuropathy
- China Neuropathic Pain Indication
  - Diabetic Neuropathy
  - Spinal Stenosis
  - Chemotherapy Induced Peripheral Neuropathy
- China Neuropathic Pain Diagnosis
  - Imaging
  - Blood Tests and Physical Examination
- China Neuropathic Pain Treatment
  - Medications
  - Multimodal Therapy
- China Neuropathic Pain End User
  - Hospitals
  - Clinics
  - Research Organization
- Japan Outlook (USD Billion, 2018-2030)
- Japan Neuropathic Pain Type
  - Painful Diabetic Peripheral Neuropathy
  - Autonomic Neuropathy
  - Focal Neuropathy
  - Proximal Neuropathy
- Japan Neuropathic Pain Indication
  - Diabetic Neuropathy
  - Spinal Stenosis
  - Chemotherapy Induced Peripheral Neuropathy
- Japan Neuropathic Pain Diagnosis
  - Imaging
  - Blood Tests and Physical Examination
- Japan Neuropathic Pain Treatment
  - Medications
  - Multimodal Therapy
- Japan Neuropathic Pain End User
  - Hospitals
  - Clinics
  - Research Organization
- India Outlook (USD Billion, 2018-2030)
- India Neuropathic Pain Type
  - Painful Diabetic Peripheral Neuropathy
  - Autonomic Neuropathy
  - Focal Neuropathy
  - Proximal Neuropathy
- India Neuropathic Pain Indication
  - Diabetic Neuropathy
  - Spinal Stenosis
  - Chemotherapy Induced Peripheral Neuropathy
- India Neuropathic Pain Diagnosis
  - Imaging
  - Blood Tests and Physical Examination
- India Neuropathic Pain Treatment
  - Medications
  - Multimodal Therapy
- India Neuropathic Pain End User
  - Hospitals
  - Clinics
  - Research Organization
- Australia Outlook (USD Billion, 2018-2030)
- Australia Neuropathic Pain Type
  - Painful Diabetic Peripheral Neuropathy
  - Autonomic Neuropathy
  - Focal Neuropathy
  - Proximal Neuropathy
- Australia Neuropathic Pain Indication
  - Diabetic Neuropathy
  - Spinal Stenosis
  - Chemotherapy Induced Peripheral Neuropathy
- Australia Neuropathic Pain Diagnosis
  - Imaging
  - Blood Tests and Physical Examination
- Australia Neuropathic Pain Treatment
  - Medications
  - Multimodal Therapy
- Australia Neuropathic Pain End User
  - Hospitals
  - Clinics
  - Research Organization
- Rest of Asia-Pacific Outlook (USD Billion, 2018-2030)
- Rest of Asia-Pacific Neuropathic Pain Type
  - Painful Diabetic Peripheral Neuropathy
  - Autonomic Neuropathy
  - Focal Neuropathy
  - Proximal Neuropathy
- Rest of Asia-Pacific Neuropathic Pain Indication
  - Diabetic Neuropathy
  - Spinal Stenosis
  - Chemotherapy Induced Peripheral Neuropathy
- Rest of Asia-Pacific Neuropathic Pain Diagnosis
  - Imaging
  - Blood Tests and Physical Examination
- Rest of Asia-Pacific Neuropathic Pain Treatment
  - Medications
  - Multimodal Therapy
- Rest of Asia-Pacific Neuropathic Pain End User
  - Hospitals
  - Clinics
  - Research Organization

Rest of the World Outlook (USD Billion, 2018-2030)
- Rest of the World Neuropathic Pain Type
  - Painful Diabetic Peripheral Neuropathy
  - Autonomic Neuropathy
  - Focal Neuropathy
  - Proximal Neuropathy
- Rest of the World Neuropathic Pain Indication
  - Diabetic Neuropathy
  - Spinal Stenosis
  - Chemotherapy Induced Peripheral Neuropathy
- Rest of the World Neuropathic Pain Diagnosis
  - Imaging
  - Blood Tests and Physical Examination
- Rest of the World Neuropathic Pain Treatment
  - Medications
  - Multimodal Therapy
- Rest of the World Neuropathic Pain End User
  - Hospitals
  - Clinics
  - Research Organization
- Middle East Outlook (USD Billion, 2018-2030)
- Middle East Neuropathic Pain Type
  - Painful Diabetic Peripheral Neuropathy
  - Autonomic Neuropathy
  - Focal Neuropathy
  - Proximal Neuropathy
- Middle East Neuropathic Pain Indication
  - Diabetic Neuropathy
  - Spinal Stenosis
  - Chemotherapy Induced Peripheral Neuropathy
- Middle East Neuropathic Pain Diagnosis
  - Imaging
  - Blood Tests and Physical Examination
- Middle East Neuropathic Pain Treatment
  - Medications
  - Multimodal Therapy
- Middle East Neuropathic Pain End User
  - Hospitals
  - Clinics
  - Research Organization
- Africa Outlook (USD Billion, 2018-2030)
- Africa Neuropathic Pain Type
  - Painful Diabetic Peripheral Neuropathy
  - Autonomic Neuropathy
  - Focal Neuropathy
  - Proximal Neuropathy
- Africa Neuropathic Pain Indication
  - Diabetic Neuropathy
  - Spinal Stenosis
  - Chemotherapy Induced Peripheral Neuropathy
- Africa Neuropathic Pain Diagnosis
  - Imaging
  - Blood Tests and Physical Examination
- Africa Neuropathic Pain Treatment
  - Medications
  - Multimodal Therapy
- Africa Neuropathic Pain End User
  - Hospitals
  - Clinics
  - Research Organization
- Latin America Outlook (USD Billion, 2018-2030)
- Latin America Neuropathic Pain Type
  - Painful Diabetic Peripheral Neuropathy
  - Autonomic Neuropathy
  - Focal Neuropathy
  - Proximal Neuropathy
- Latin America Neuropathic Pain Indication
  - Diabetic Neuropathy
  - Spinal Stenosis
  - Chemotherapy Induced Peripheral Neuropathy
- Latin America Neuropathic Pain Diagnosis
  - Imaging
  - Blood Tests and Physical Examination
- Latin America Neuropathic Pain Treatment
  - Medications
  - Multimodal Therapy
- Latin America Neuropathic Pain End User
  - Hospitals
  - Clinics
  - Research Organization

Research Methodology on Neuropathic Pain Market

Market Research Future (MRFR) follows an extensive and comprehensive research methodology involving both primary and secondary sources of data collection. For the evaluation of data collected through primary sources, secondary sources, or both primary and secondary sources, we have used the Qualitative & Quantitative Research approaches.

Primary Research:

The primary source of data collection includes interviews with industry experts, such as C-level executives (CEOs, CTOs, and CFOs), directors, and other experts. MRFR conducted 130 interviews with industry thought leaders and other stakeholders to gain insights into the Neuropathic Pain Market. With this MRFR has gathered pertinent information about the factors driving the Neuropathic Pain Market and those hampering the market's growth.

Secondary Research:

The secondary research includes online sources such as press releases of companies, journals, and databases; relevant publications and official documents; websites; and investor presentations of industry participants. Moreover, MRFR has conducted a market analysis and studied the competitive landscape of the Neuropathic Pain Market.

Data Collection and Validation

The data collected through both primary and secondary sources are comprehensively analyzed and validated through the triangulation method. The data is also moderated and fine-tuned through data mining, interviews, and opinions gathered from industry experts.

Research Assumptions

The estimates of the market size and shares provided in the report are made after a thorough analysis of market data and information. The assumptions taken into consideration are as follows:

Global Neuropathic Pain Market is expected to register an all-time high growth rate during the forecast period of 2023–2030.

Neuropathic pain is more prevalent in older patients, and the increase in the global geriatric population is fuelling the growth of the Neuropathic Pain Market.

Innovations in therapeutics such as drugs, combination therapies, and treatments with emerging technologies are increasing market opportunities.

Increasing adoption of neuropathic pain treatments in developing countries is expected to drive the growth of the Neuropathic Pain Market.

Despite the numerous growth drivers, side effects associated with neuropathic pain drugs are projected to restrain the market.

Market Segmentation

The Neuropathic Pain Market is segmented based on type, drug class, route of administration, and region.

On the basis of type, the Neuropathic Pain Market is segmented into neuropathic pain caused by diabetes, cancer, HIV/aids, shingles, and others.

Based on drug class, the Neuropathic Pain Market is segmented into antidepressants, antiepileptics, topical products, opioids, and others.

On the basis of the route of administration, the Neuropathic Pain Market is segmented into oral, injected, and topical.

Target Audience

Pharmaceutical Companies

Neuropathic Pain Association

Academic Researchers

Investors and Venture Capitalists

Regulatory Bodies

Healthcare Professionals

Market Research and Consulting Firms

Regional Analysis

The Neuropathic Pain Market is segmented into five major regions: North America, Europe, Asia-Pacific, the Middle East & Africa, and Latin America.

North America is expected to account for the largest market share owing to the presence of well-established healthcare infrastructure and the existence of sophisticated therapeutic practices and better access to medicines. The rising cases of neuropathic pain are likely to boost the growth of the Neuropathic Pain Market in this region.

Europe is expected to follow North America in terms of market share. The developed healthcare infrastructure and research & development support are critical components that facilitate the expansion of the Neuropathic Pain Market in this region.

Asia-Pacific is likely to be the fastest-growing region in the Neuropathic Pain Market due to the increasing geriatric population, technological advancement in product development, and rapid industrialization in the region.

The Middle East & Africa are projected to account for a significant market share due to the rising awareness about neuropathic pain and its increasing prevalence.

Latin America is expected to register a moderate growth rate over the forecast period mainly due to a lack of awareness and facilities for neurologically related treatments.

Key Players

The key players of the global Neuropathic Pain Market are GlaxoSmithKline plc (UK), Johnson & Johnson Services Inc. (US), Eli Lilly and Company (US), Pfizer Inc. (US), AstraZeneca plc (UK), Valeant Pharmaceuticals (US), Novartis AG (Switzerland), Sanofi S.A. (France), Allergan plc (Ireland), and Teva Pharmaceutical Industries Ltd. (Israel), among others.

Leading companies partner with us for data-driven Insights

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION 22

2.2 SCOPE OF THE STUDY 22

2.3 RESEARCH OBJECTIVE 22

2.4 MARKET STRUCTURE 23

2.5 ASSUMPTIONS & LIMITATIONS 24

3 RESEARCH METHODOLOGY

3.1 DATA MINING 25

3.2 SECONDARY RESEARCH 26

3.3 PRIMARY RESEARCH 27

3.4 BREAKDOWN OF PRIMARY RESPONDENTS 28

3.5 FORECASTING TECHNIQUES 29

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 30

3.6.1 BOTTOM-UP APPROACH 31

3.6.2 TOP-DOWN APPROACH 31

3.7 DATA TRIANGULATION 32

3.8 VALIDATION 32

4 MARKET DYNAMICS

4.1 OVERVIEW 33

4.2 DRIVERS 34

4.2.1 RISING PREVALENCE OF DIABETIC NEUROPATHY 34

4.2.2 INCREASING HEALTHCARE EXPENDITURE 34

4.2.3 GROWING NUMBER OF INCIDENCE OF TRAUMA FROM INJURY AND OTHER CONDITIONS 35

4.3 RESTRAINTS 36

4.3.1 INCREASING COUNTERFEIT DRUGS & SIDE EFFECTS OF THE THERAPEUTIC TREATMENT 36

4.3.2 LACK OF AWARENESS ABOUT THE NEUROLOGICAL CONDITION 37

4.4 OPPORTUNITIES 38

4.4.1 NEW PRODUCT LAUNCH IN DEVELOPING REGIONS 38

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS 39

5.1.1 R&D 40

5.1.2 MANUFACTURING 40

5.1.3 DISTRIBUTION AND SALES 40

5.1.4 POST-SALES MONITORING 40

5.2 PORTER’S FIVE FORCES MODEL 41

5.2.1 BARGAINING POWER OF SUPPLIERS 42

5.2.2 BARGAINING POWER OF BUYERS 42

5.2.3 THREAT OF NEW ENTRANTS 42

5.2.4 THREAT OF SUBSTITUTES 42

5.2.5 INTENSITY OF RIVALRY 42

5.3 IMPACT ANALYSIS OF COVID-19 ON THE GLOBAL NEUROPATHIC PAIN MARKET 43

5.3.1 OVERVIEW 43

5.3.2 IMPACT ON ONGOING TREATMENTS AND DELAYED AVAILABILITY DUE TO DEFERMENT 43

5.3.3 IMPACT ON NUMBER OF PATIENTS 44

6 GLOBAL NEUROPATHIC PAIN MARKET, BY TYPE

6.1 OVERVIEW 45

6.2 PERIPHERAL NEUROPATHY 47

6.3 ENTRAPMENT NEUROPATHY 47

6.4 TRIGEMINAL NEURALGIA 48

6.5 PHANTOM LIMB PAIN 48

6.6 POST HERPETIC NEURALGIA (PHN) 49

6.7 POST TRAUMATIC NEUROPATHY 49

7 GLOBAL NEUROPATHIC PAIN MARKET, BY INDICATION

7.1 OVERVIEW 50

7.2 DIABETIC NEUROPATHY 52

7.3 SPINAL STENOSIS 52

7.4 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY 53

7.5 OTHERS 53

8 GLOBAL NEUROPATHIC PAIN MARKET, BY DIAGNOSIS

8.1 OVERVIEW 54

8.2 IMAGING 55

8.3 BLOOD TESTS 56

8.4 PHYSICAL EXAMINATION 56

9 GLOBAL NEUROPATHIC PAIN MARKET, BY TREATMENT

9.1 OVERVIEW 57

9.2 MEDICATION 58

9.3 MULTIMODAL THERAPY 60

10 GLOBAL NEUROPATHIC PAIN SMARKET, BY DISTRIBUTION CHANNEL

10.1 OVERVIEW 61

10.2 RETAIL PHARMACIES & DRUG STORES 62

10.3 ONLINE PHARMACIES 62

11 GLOBAL NEUROPATHIC PAIN MARKET, BY END USER

11.1 OVERVIEW 63

11.2 HOSPITALS 64

11.3 CLINICS 64

11.4 RESEARCH ORGANIZATIONS 65

12 GLOBAL NEUROPATHIC PAIN MARKET, BY REGION

12.1 OVERVIEW 66

12.2 AMERICAS 67

12.2.1 NORTH AMERICA 72

12.2.1.1 US 77

12.2.1.2 CANADA 81

12.2.2 LATIN AMERICA 85

12.3 EUROPE 90

12.3.1 WESTERN EUROPE 95

12.3.1.1 GERMANY 100

12.3.1.2 UK 104

12.3.1.3 FRANCE 108

12.3.1.4 ITALY 112

12.3.1.5 SPAIN 116

12.3.1.6 REST OF WESTERN EUROPE 120

12.3.2 EASTERN EUROPE 124

12.4 ASIA-PACIFIC 129

12.4.1 CHINA 134

12.4.2 INDIA 138

12.4.3 JAPAN 142

12.4.4 SOUTH KOREA 146

12.4.5 AUSTRALIA 150

12.4.6 REST OF ASIA-PACIFIC 154

12.5 MIDDLE EAST & AFRICA 159

12.5.1 MIDDLE EAST 164

12.5.2 AFRICA 168

13 COMPETITIVE LANDSCAPE

13.1 OVERVIEW 173

13.2 COMPETITIVE BENCHMARKING 174

13.3 GLOBAL NEUROPATHIC PAIN MARKET: COMPANY RANKING, 2020 175

13.4 MAJOR GROWTH STRATEGY IN THE GLOBAL NEUROPATHIC PAIN MARKET 175

13.5 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS 176

13.6 COMPETITIVE BENCHMARKING: GLOBAL NEUROPATHIC PAIN MARKET 176

13.7 KEY DEVELOPMENTS & GROWTH STRATEGIES 177

13.7.1 PRODUCT APPROVALS AND LAUNCHES 177

13.7.2 ACQUISITIONS 177

13.8 FINANCIAL MATRIX 178

14 COMPANY PROFILES

14.1 ABBOTT 179

14.1.1 COMPANY OVERVIEW 179

14.1.2 FINANCIAL OVERVIEW 180

14.1.3 PRODUCTS/SERVICES OFFERED 180

14.1.4 KEY DEVELOPMENTS 181

14.1.5 SWOT ANALYSIS 182

14.1.6 KEY STRATEGIES 182

14.2 PFIZER 183

14.2.1 COMPANY OVERVIEW 183

14.2.2 FINANCIAL OVERVIEW 183

14.2.3 PRODUCTS/SERVICES OFFERED 184

14.2.4 KEY DEVELOPMENTS 184

14.2.5 SWOT ANALYSIS 184

14.2.6 KEY STRATEGIES 184

14.3 JOHNSON & JOHNSON SERVICES, INC. 185

14.3.1 COMPANY OVERVIEW 185

14.3.2 FINANCIAL OVERVIEW 186

14.3.3 PRODUCTS/SERVICES OFFERED 186

14.3.4 KEY DEVELOPMENTS 186

14.3.5 SWOT ANALYSIS 187

14.3.6 KEY STRATEGIES 187

14.4 BAXTER INTERNATIONAL 188

14.4.1 COMPANY OVERVIEW 188

14.4.2 FINANCIAL OVERVIEW 188

14.4.3 PRODUCTS/SERVICES OFFERED 189

14.4.4 KEY DEVELOPMENTS 189

14.4.5 SWOT ANALYSIS 189

14.4.6 KEY STRATEGIES 190

14.5 ELI LILY AND COMPANY 190

14.5.1 COMPANY OVERVIEW 190

14.5.2 FINANCIAL OVERVIEW 191

14.5.3 PRODUCTS/SERVICES OFFERED 191

14.5.4 KEY DEVELOPMENTS 191

14.5.5 SWOT ANALYSIS 192

14.5.6 KEY STRATEGIES 192

14.6 GLAXOSMITHKLINE PLC 193

14.6.1 COMPANY OVERVIEW 193

14.6.2 FINANCIAL OVERVIEW 193

14.6.3 PRODUCTS/SERVICES OFFERED 194

14.6.4 KEY DEVELOPMENTS 194

14.6.5 SWOT ANALYSIS 194

14.6.6 KEY STRATEGIES 195

14.7 SANOFI 195

14.7.1 COMPANY OVERVIEW 195

14.7.2 FINANCIAL OVERVIEW 196

14.7.3 PRODUCTS/SERVICES OFFERED 196

14.7.4 KEY DEVELOPMENTS 197

14.7.5 SWOT ANALYSIS 197

14.7.6 KEY STRATEGIES 197

14.8 ASTRAZENECA 198

14.8.1 COMPANY OVERVIEW 198

14.8.2 FINANCIAL OVERVIEW 198

14.8.3 PRODUCTS/SERVICES OFFERED 199

14.8.4 KEY DEVELOPMENTS 199

14.8.5 SWOT ANALYSIS 199

14.8.6 KEY STRATEGIES 199

14.9 DEPOMED INC. (ASSERTIO THERAPEUTICS, INC) 200

14.9.1 COMPANY OVERVIEW 200

14.9.2 FINANCIAL OVERVIEW 200

14.9.3 PRODUCTS/SERVICES OFFERED 200

14.9.4 KEY DEVELOPMENTS 201

14.9.5 SWOT ANALYSIS 201

14.9.6 KEY STRATEGIES 202

14.10 BIOGEN, INC. 202

14.10.1 COMPANY OVERVIEW 202

14.10.2 FINANCIAL OVERVIEW 202

14.10.3 PRODUCTS/SERVICES OFFERED 203

14.10.4 KEY DEVELOPMENTS 203

14.10.5 SWOT ANALYSIS 203

14.10.6 KEY STRATEGIES 203

14.11 ASTELLAS PHARMA LTD. 204

14.11.1 COMPANY OVERVIEW 204

14.11.2 FINANCIAL OVERVIEW 204

14.11.3 PRODUCTS/SERVICES OFFERED 205

14.11.4 KEY DEVELOPMENTS 205

14.11.5 SWOT ANALYSIS 205

14.11.6 KEY STRATEGIES 206

15 APPENDIX

15.1 REFERENCES 207

15.2 RELATED REPORTS 207

16 LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 24

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 27

TABLE 3 GLOBAL NEUROPATHIC PAIN MARKET, BY TYPE, 2022-2030 (USD MILLION) 46

TABLE 4 GLOBAL NEUROPATHIC PAIN MARKET FOR PERIPHERAL NEUROPATHY, BY REGION, 2022-2030 (USD MILLION) 47

TABLE 5 GLOBAL NEUROPATHIC PAIN MARKET FOR ENTRAPMENT NEUROPATHY, BY REGION, 2022-2030 (USD MILLION) 47

TABLE 6 GLOBAL NEUROPATHIC PAIN MARKET FOR TRIGEMINAL NEURALGIA, BY REGION, 2022-2030 (USD MILLION) 48

TABLE 7 GLOBAL NEUROPATHIC PAIN MARKET FOR PHANTOM LIMB PAIN, BY REGION, 2022-2030 (USD MILLION) 48

TABLE 8 GLOBAL NEUROPATHIC PAIN MARKET FOR POST HERPETIC NEURALGIA (PHN), BY REGION, 2022-2030 (USD MILLION) 49

TABLE 9 GLOBAL NEUROPATHIC PAIN MARKET FOR POST TRAUMATIC NEUROPATHY, BY REGION, 2022-2030(USD MILLION) 49

TABLE 10 GLOBAL NEUROPATHIC PAIN MARKET, BY INDICATION, 2020-2029 (USD MILLION) 51

TABLE 11 GLOBAL NEUROPATHIC PAIN MARKET, FOR DIABETIC NEUROPATHY, BY REGION 2020-2029 (USD MILLION) 52

TABLE 12 GLOBAL NEUROPATHIC PAIN MARKET, FOR DIABETIC NEUROPATHY, BY TYPE 2020-2029 (USD MILLION) 52

TABLE 13 GLOBAL NEUROPATHIC PAIN MARKET, FOR SPINAL STENOSIS, BY REGION, 2020-2029 (USD MILLION) 52

TABLE 14 GLOBAL NEUROPATHIC PAIN MARKET, FOR CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY, BY REGION 2020-2029 (USD MILLION) 53

TABLE 15 GLOBAL NEUROPATHIC PAIN MARKET, FOR OTHERS, BY REGION, 2020-2029 (USD MILLION) 53

TABLE 16 GLOBAL NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION) 55

TABLE 17 GLOBAL NEUROPATHIC PAIN MARKET FOR IMAGING, BY REGION, 2022-2030 (USD MILLION) 55

TABLE 18 GLOBAL NEUROPATHIC PAIN MARKET BY IMAGING TYPE, 2022-2030 (USD MILLION) 55

TABLE 19 GLOBAL NEUROPATHIC PAIN MARKET FOR BLOOD TESTS, BY REGION, 2022-2030 (USD MILLION) 56

TABLE 20 GLOBAL NEUROPATHIC PAIN MARKET FOR PHYSICAL EXAMINATION, BY REGION, 2022-2030 (USD MILLION) 56

TABLE 21 GLOBAL NEUROPATHIC PAIN MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 58

TABLE 22 GLOBAL NEUROPATHIC PAIN MARKET FOR MEDICATION, BY REGION, 2022-2030 (USD MILLION) 58

TABLE 23 GLOBAL NEUROPATHIC PAIN MARKET BY MEDICATION TYPE, 2022-2030 (USD MILLION) 59

TABLE 24 GLOBAL NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2022-2030 (USD MILLION) 59

TABLE 25 GLOBAL NEUROPATHIC PAIN MARKET BY ANTIDEPRESSANT DRUGS, 2022-2030 (USD MILLION) 59

TABLE 26 GLOBAL NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2022-2030 (USD MILLION) 60

TABLE 27 GLOBAL NEUROPATHIC PAIN MARKET FOR MULTIMODAL THERAPY, BY REGION, 2022-2030 (USD MILLION) 60

TABLE 28 GLOBAL NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION) 62

TABLE 29 GLOBAL NEUROPATHIC PAIN MARKET FOR RETAIL PHARMACIES & DRUG STORES, BY REGION, 2022-2030 (USD MILLION) 62

TABLE 30 GLOBAL NEUROPATHIC PAIN MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2030 (USD MILLION) 62

TABLE 31 GLOBAL NEUROPATHIC PAIN MARKET, BY END USER, 2022-2030 (USD MILLION) 64

TABLE 32 GLOBAL NEUROPATHIC PAIN MARKET FOR HOSPITALS, BY REGION, 2022-2030 (USD MILLION) 64

TABLE 33 GLOBAL NEUROPATHIC PAIN MARKET FOR CLINICS, BY REGION, 2022-2030 (USD MILLION) 64

TABLE 34 GLOBAL NEUROPATHIC PAIN MARKET FOR RESEARCH ORGANIZATIONS, BY REGION, 2022-2030 (USD MILLION) 65

TABLE 35 GLOBAL NEUROPATHIC PAIN MARKET, BY REGION, 2022-2030 (USD MILLION) 66

TABLE 36 AMERICAS: NEUROPATHIC PAIN MARKET, BY REGION, 2022-2030 (USD MILLION) 67

TABLE 37 AMERICAS: NEUROPATHIC PAIN MARKET, BY TYPE, 2022-2030 (USD MILLION) 68

TABLE 38 AMERICAS: NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2030 (USD MILLION) 68

TABLE 39 AMERICAS: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2022-2030 (USD MILLION) 68

TABLE 40 AMERICAS: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION) 69

TABLE 41 AMERICAS: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2022-2030 (USD MILLION) 69

TABLE 42 AMERICAS: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 69

TABLE 43 AMERICAS: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2022-2030 (USD MILLION) 70

TABLE 44 AMERICAS: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2022-2030 (USD MILLION) 70

TABLE 45 AMERICAS: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2022-2030 (USD MILLION) 70

TABLE 46 AMERICAS: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2022-2030 (USD MILLION) 71

TABLE 47 AMERICAS: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION) 71

TABLE 48 AMERICAS: NEUROPATHIC PAIN MARKET, BY END USER, 2022-2030 (USD MILLION) 71

TABLE 49 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY COUNTRY, 2022-2030 (USD MILLION) 73

TABLE 50 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY TYPE, 2022-2030 (USD MILLION) 73

TABLE 51 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2030 (USD MILLION) 73

TABLE 52 NORTH AMERICA: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2022-2030 (USD MILLION) 74

TABLE 53 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION) 74

TABLE 54 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2022-2030 (USD MILLION) 74

TABLE 55 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY TREATMENT,2022-2030 (USD MILLION) 75

TABLE 56 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2022-2030 (USD MILLION) 75

TABLE 57 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2022-2030 (USD MILLION) 75

TABLE 58 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2022-2030 (USD MILLION) 76

TABLE 59 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2022-2030 (USD MILLION) 76

TABLE 60 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION) 76

TABLE 61 NORTH AMERICA: NEUROPATHIC PAIN MARKET, BY END USER, 2022-2030 (USD MILLION) 77

TABLE 62 US: NEUROPATHIC PAIN MARKET, BY TYPE, 2022-2030 (USD MILLION) 77

TABLE 63 US: NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2030 (USD MILLION) 77

TABLE 64 US: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2022-2030 (USD MILLION) 78

TABLE 65 US: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION) 78

TABLE 66 US: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2022-2030 (USD MILLION) 78

TABLE 67 US: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 79

TABLE 68 US: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2022-2030 (USD MILLION) 79

TABLE 69 US: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2022-2030 (USD MILLION) 79

TABLE 70 US: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2022-2030 (USD MILLION) 80

TABLE 71 US: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2022-2030 (USD MILLION) 80

TABLE 72 US: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION) 80

TABLE 73 US: NEUROPATHIC PAIN MARKET, BY END USER, 2022-2030 (USD MILLION) 81

TABLE 74 CANADA: NEUROPATHIC PAIN MARKET, BY TYPE, 2022-2030 (USD MILLION) 81

TABLE 75 CANADA: NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2030 (USD MILLION) 81

TABLE 76 CANADA: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2022-2030 (USD MILLION) 82

TABLE 77 CANADA: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION) 82

TABLE 78 CANADA: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2022-2030 (USD MILLION) 82

TABLE 79 CANADA: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 83

TABLE 80 CANADA: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2022-2030 (USD MILLION) 83

TABLE 81 CANADA: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2022-2030 (USD MILLION) 83

TABLE 82 CANADA: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2022-2030 (USD MILLION) 84

TABLE 83 CANADA: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2022-2030 (USD MILLION) 84

TABLE 84 CANADA: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION) 84

TABLE 85 CANADA: NEUROPATHIC PAIN MARKET, BY END USER, 2022-2030 (USD MILLION) 85

TABLE 86 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY TYPE, 2022-2030 (USD MILLION), 85

TABLE 87 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2030 (USD MILLION) 85

TABLE 88 LATIN AMERICA: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2022-2030 (USD MILLION) 86

TABLE 89 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION) 86

TABLE 90 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2022-2030 (USD MILLION) 86

TABLE 91 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 87

TABLE 92 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2022-2030 (USD MILLION) 87

TABLE 93 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2022-2030 (USD MILLION) 87

TABLE 94 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2022-2030 (USD MILLION) 88

TABLE 95 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2022-2030 (USD MILLION) 88

TABLE 96 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION) 88

TABLE 97 LATIN AMERICA: NEUROPATHIC PAIN MARKET, BY END USER, 2022-2030 (USD MILLION) 89

TABLE 98 EUROPE: NEUROPATHIC PAIN MARKET, BY REGION, 2022-2030 (USD MILLION) 90

TABLE 99 EUROPE: NEUROPATHIC PAIN MARKET, BY TYPE, 2022-2030 (USD MILLION) 91

TABLE 100 EUROPE: NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2030 (USD MILLION) 91

TABLE 101 EUROPE: NEUROPATHIC PAIN MARKET, FOR DIABETIC NEUROPATHY, BY TYPE, 2022-2030 (USD MILLION) 91

TABLE 102 EUROPE: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION) 92

TABLE 103 EUROPE: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2022-2030 (USD MILLION) 92

TABLE 104 EUROPE: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 92

TABLE 105 EUROPE: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2022-2030 (USD MILLION) 93

TABLE 106 EUROPE: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2022-2030 (USD MILLION) 93

TABLE 107 EUROPE: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2022-2030 (USD MILLION) 93

TABLE 108 EUROPE: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2022-2030 (USD MILLION) 94

TABLE 109 EUROPE: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION) 94

TABLE 110 EUROPE: NEUROPATHIC PAIN MARKET, BY END USER, 2022-2030 (USD MILLION) 94

TABLE 111 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY COUNTRY, 2022-2030 (USD MILLION) 95

TABLE 112 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY TYPE, 2022-2030 (USD MILLION) 96

TABLE 113 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2030 (USD MILLION) 96

TABLE 114 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, FOR DIABETIC NEUROPATHY, BY TYPE, 2022-2030 (USD MILLION) 97

TABLE 115 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION) 97

TABLE 116 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2022-2030 (USD MILLION) 97

TABLE 117 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 98

TABLE 118 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2022-2030 (USD MILLION) 98

TABLE 119 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2022-2030 (USD MILLION) 98

TABLE 120 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2022-2030 (USD MILLION) 99

TABLE 121 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2022-2030 (USD MILLION) 99

TABLE 122 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION) 99

TABLE 123 WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY END USER, 2022-2030 (USD MILLION) 100

TABLE 124 GERMANY NEUROPATHIC PAIN MARKET, BY TYPE, 2022-2030 (USD MILLION) 100

TABLE 125 GERMANY: NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2030 (USD MILLION) 100

TABLE 126 GERMANY: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2022-2030 (USD MILLION) 101

TABLE 127 GERMANY: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION) 101

TABLE 128 GERMANY: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2022-2030 (USD MILLION) 101

TABLE 129 GERMANY: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 102

TABLE 130 GERMANY: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2022-2030 (USD MILLION) 102

TABLE 131 GERMANY: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2022-2030 (USD MILLION) 102

TABLE 132 GERMANY: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2022-2030 (USD MILLION) 103

TABLE 133 GERMANY: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2022-2030 (USD MILLION) 103

TABLE 134 GERMANY: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION) 103

TABLE 135 GERMANY: NEUROPATHIC PAIN MARKET, BY END USER, 2022-2030 (USD MILLION) 104

TABLE 136 UK: NEUROPATHIC PAIN MARKET, BY TYPE, 2022-2030 (USD MILLION) 104

TABLE 137 UK: NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2030 (USD MILLION) 104

TABLE 138 UK: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2022-2030 (USD MILLION) 105

TABLE 139 UK: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION) 105

TABLE 140 UK: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2022-2030 (USD MILLION) 105

TABLE 141 UK: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 106

TABLE 142 UK: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2022-2030 (USD MILLION) 106

TABLE 143 UK: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2022-2030 (USD MILLION) 106

TABLE 144 UK: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2022-2030 (USD MILLION) 107

TABLE 145 UK: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2022-2030 (USD MILLION) 107

TABLE 146 UK: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION) 107

TABLE 147 UK: NEUROPATHIC PAIN MARKET, BY END USER, 2022-2030 (USD MILLION) 108

TABLE 148 FRANCE: NEUROPATHIC PAIN MARKET, BY TYPE, 2022-2030 (USD MILLION) 108

TABLE 149 FRANCE: NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2030 (USD MILLION) 108

TABLE 150 FRANCE: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2022-2030 (USD MILLION) 109

TABLE 151 FRANCE: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION) 109

TABLE 152 FRANCE: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2022-2030 (USD MILLION) 109

TABLE 153 FRANCE: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 110

TABLE 154 FRANCE: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2022-2030 (USD MILLION) 110

TABLE 155 FRANCE: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2022-2030 (USD MILLION) 110

TABLE 156 FRANCE: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2022-2030 (USD MILLION) 111

TABLE 157 FRANCE: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2022-2030 (USD MILLION) 111

TABLE 158 FRANCE: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION) 111

TABLE 159 FRANCE: NEUROPATHIC PAIN MARKET, BY END USER, 2022-2030 (USD MILLION) 112

TABLE 160 ITALY: NEUROPATHIC PAIN MARKET, BY TYPE, 2022-2030 (USD MILLION) 112

TABLE 161 ITALY: NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2030 (USD MILLION) 112

TABLE 162 ITALY: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2022-2030 (USD MILLION) 113

TABLE 163 ITALY: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION) 113

TABLE 164 ITALY: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2022-2030 (USD MILLION) 113

TABLE 165 ITALY: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 114

TABLE 166 ITALY: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2022-2030 (USD MILLION) 114

TABLE 167 ITALY: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2022-2030 (USD MILLION) 114

TABLE 168 ITALY: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2022-2030 (USD MILLION) 115

TABLE 169 ITALY: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2022-2030 (USD MILLION) 115

TABLE 170 ITALY: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION) 115

TABLE 171 ITALY: NEUROPATHIC PAIN MARKET, BY END USER, 2022-2030 (USD MILLION) 116

TABLE 172 SPAIN: NEUROPATHIC PAIN MARKET, BY TYPE, 2022-2030 (USD MILLION) 116

TABLE 173 SPAIN: NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2030 (USD MILLION) 116

TABLE 174 SPAIN: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2022-2030 (USD MILLION) 117

TABLE 175 SPAIN: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION) 117

TABLE 176 SPAIN: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2022-2030 (USD MILLION) 117

TABLE 177 SPAIN: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 118

TABLE 178 SPAIN: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2022-2030 (USD MILLION) 118

TABLE 179 SPAIN: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2022-2030 (USD MILLION) 118

TABLE 180 SPAIN: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2022-2030 (USD MILLION) 119

TABLE 181 SPAIN: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2022-2030 (USD MILLION) 119

TABLE 182 SPAIN: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION) 119

TABLE 183 SPAIN: NEUROPATHIC PAIN MARKET, BY END USER, 2022-2030 (USD MILLION) 120

TABLE 184 REST OF WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY TYPE, 2022-2030 (USD MILLION) 120

TABLE 185 REST OF WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2030 (USD MILLION) 120

TABLE 186 REST OF WESTERN EUROPE: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2022-2030 (USD MILLION) 121

TABLE 187 REST OF WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION) 121

TABLE 188 REST OF WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2022-2030 (USD MILLION) 121

TABLE 189 REST OF WESTERN EUROPE NEUROPATHIC PAIN MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 122

TABLE 190 REST OF WESTERN EUROPE NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2022-2030 (USD MILLION) 122

TABLE 191 REST OF WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2022-2030 (USD MILLION) 122

TABLE 192 REST OF WESTERN EUROPE NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2022-2030 (USD MILLION) 123

TABLE 193 REST OF WESTERN EUROPE” NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2022-2030 (USD MILLION) 123

TABLE 194 REST OF WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION) 123

TABLE 195 REST OF WESTERN EUROPE: NEUROPATHIC PAIN MARKET, BY END USER, 2022-2030 (USD MILLION) 124

TABLE 196 EASTERN EUROPE: NEUROPATHIC PAIN MARKET, BY TYPE, 2022-2030 (USD MILLION) 124

TABLE 197 EASTERN EUROPE: NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2030 (USD MILLION) 125

TABLE 198 EASTERN EUROPE: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2022-2030 (USD MILLION) 125

TABLE 199 EASTERN EUROPE: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION) 125

TABLE 200 EASTERN EUROPE: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2022-2030 (USD MILLION) 126

TABLE 201 EASTERN EUROPE: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 126

TABLE 202 EASTERN EUROPE NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2022-2030 (USD MILLION) 126

TABLE 203 EASTERN EUROPE: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2022-2030 (USD MILLION) 127

TABLE 204 EASTERN EUROPE NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2022-2030 (USD MILLION) 127

TABLE 205 EASTERN EUROPE: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2022-2030 (USD MILLION) 127

TABLE 206 EASTERN EUROPE: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION) 128

TABLE 207 EASTERN EUROPE: NEUROPATHIC PAIN MARKET, BY END USER, 2022-2030 (USD MILLION) 128

TABLE 208 ASIA-PACIFIC: NEUROPATHIC PAIN MARKET, BY COUNTRY, 2022-2030 (USD MILLION) 129

TABLE 209 ASIA-PACIFIC: NEUROPATHIC PAIN MARKET, BY TYPE, 2022-2030 (USD MILLION) 130

TABLE 210 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2030 (USD MILLION) 130

TABLE 211 ASIA-PACIFIC: NEUROPATHIC PAIN MARKET, FOR DIABETIC NEUROPATHY, BY TYPE, 2022-2030 (USD MILLION) 131

TABLE 212 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION) 131

TABLE 213 ASIA-PACIFIC: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2022-2030 (USD MILLION) 131

TABLE 214 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 132

TABLE 215 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2022-2030 (USD MILLION) 132

TABLE 216 ASIA-PACIFIC: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2022-2030 (USD MILLION) 132

TABLE 217 ASIA-PACIFIC: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2022-2030 (USD MILLION) 133

TABLE 218 ASIA-PACIFIC NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2022-2030 (USD MILLION) 133

TABLE 219 ASIA-PACIFIC: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION) 133

TABLE 220 ASIA-PACIFIC: NEUROPATHIC PAIN MARKET, BY END USER, 2022-2030 (USD MILLION) 134

TABLE 221 CHINA: NEUROPATHIC PAIN MARKET, BY TYPE, 2022-2030 (USD MILLION) 134

TABLE 222 CHINA NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2030 (USD MILLION) 134

TABLE 223 CHINA NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2022-2030 (USD MILLION) 135

TABLE 224 CHINA NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION) 135

TABLE 225 CHINA: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2022-2030 (USD MILLION) 135

TABLE 226 CHINA: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 136

TABLE 227 CHINA: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2022-2030 (USD MILLION) 136

TABLE 228 CHINA: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2022-2030 (USD MILLION) 136

TABLE 229 CHINA: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2022-2030 (USD MILLION) 137

TABLE 230 CHINA: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2022-2030 (USD MILLION) 137

TABLE 231 CHINA: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION) 137

TABLE 232 CHINA: NEUROPATHIC PAIN MARKET, BY END USER, 2022-2030 (USD MILLION) 138

TABLE 233 INDIA: NEUROPATHIC PAIN MARKET, BY TYPE, 2022-2030 (USD MILLION) 138

TABLE 234 INDIA: NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2030 (USD MILLION) 138

TABLE 235 INDIA: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2022-2030 (USD MILLION) 139

TABLE 236 INDIA: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION) 139

TABLE 237 INDIA: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2022-2030 (USD MILLION) 139

TABLE 238 INDIA: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 140

TABLE 239 INDIA: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2022-2030 (USD MILLION) 140

TABLE 240 INDIA: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2022-2030 (USD MILLION) 140

TABLE 241 INDIA: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2022-2030 (USD MILLION) 141

TABLE 242 INDIA: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2022-2030 (USD MILLION) 141

TABLE 243 INDIA: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION) 141

TABLE 244 INDIA: NEUROPATHIC PAIN MARKET, BY END USER, 2022-2030 (USD MILLION) 142

TABLE 245 JAPAN: NEUROPATHIC PAIN MARKET, BY TYPE, 2022-2030 (USD MILLION) 142

TABLE 246 JAPAN: NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2030 (USD MILLION) 142

TABLE 247 JAPAN: NEUROPATHIC PAIN MARKET, FOR DIABETIC NEUROPATHY, BY TYPE, 2022-2030 (USD MILLION) 143

TABLE 248 JAPAN: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION) 143

TABLE 249 JAPAN: NEUROPATHIC PAIN MARKET, BY IMAGING TYPE, 2022-2030 (USD MILLION) 143

TABLE 250 JAPAN: NEUROPATHIC PAIN MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 144

TABLE 251 JAPAN: NEUROPATHIC PAIN MARKET, BY MEDICATION TYPE, 2022-2030 (USD MILLION) 144

TABLE 252 JAPAN: NEUROPATHIC PAIN MARKET, BY NSAIDS TYPE, 2022-2030 (USD MILLION) 144

TABLE 253 JAPAN: NEUROPATHIC PAIN MARKET, BY ANTIDEPRESSANT DRUGS TYPE, 2022-2030 (USD MILLION) 145

TABLE 254 JAPAN: NEUROPATHIC PAIN MARKET, BY NERVE BLOCKS TYPE, 2022-2030 (USD MILLION) 145

TABLE 255 JAPAN: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION) 145

TABLE 256 JAPAN: NEUROPATHIC PAIN MARKET, BY END USER, 2022-2030 (USD MILLION) 146

TABLE 257 SOUTH KOREA: NEUROPATHIC PAIN MARKET, BY TYPE, 2022-2030 (USD MILLION) 146

TABLE 258 SOUTH KOREA NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2030 (USD MILLION) 146

TABLE 259 SOUTH KOREA: NEUROPATHIC PAIN MARKET FOR DIABETIC NEUROPATHY, BY TYPE, 2022-2030 (USD MILLION) 147

TABLE 260 SOUTH KOREA: NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION) 147

17 LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS 21

FIGURE 2 GLOBAL NEUROPATHIC PAIN MARKET 23

FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES 30

FIGURE 4 MARKET DYNAMICS: NEUROPATHIC PAIN MARKET 33

FIGURE 5 DRIVER IMPACT ANALYSIS 36

FIGURE 6 RESTRAINT IMPACT ANALYSIS 38

FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL NEUROPATHIC PAIN MARKET 39

FIGURE 8 PORTER’S FIVE FORCES ANALYSIS: GLOBAL NEUROPATHIC PAIN MARKET 41

FIGURE 9 GLOBAL NEUROPATHIC PAIN MARKET, BY TYPE, 2022-2030 (USD MILLION) 46

FIGURE 10 GLOBAL NEUROPATHIC PAIN MARKET, BY INDICATION, 2022-2030 (USD MILLION) 51

FIGURE 11 GLOBAL NEUROPATHIC PAIN MARKET, BY DIAGNOSIS, 2022-2030 (USD MILLION) 54

FIGURE 12 GLOBAL NEUROPATHIC PAIN MARKET, BY TREATMENT, 2022-2030 (USD MILLION) 58

FIGURE 13 GLOBAL NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION) 61

FIGURE 14 GLOBAL NEUROPATHIC PAIN MARKET, BY END USER, 2022-2030 (USD MILLION) 63

FIGURE 15 GLOBAL NEUROPATHIC PAIN MARKET, BY REGION, 2022-2030 (USD MILLION) 66

FIGURE 16 AMERICAS: NEUROPATHIC PAIN MARKET SHARE, BY REGION, 2020 (%) 67

FIGURE 17 NORTH AMERICA: NEUROPATHIC PAIN MARKET SHARE, BY COUNTRY, 2020 (%) 72

FIGURE 18 EUROPE: NEUROPATHIC PAIN MARKET SHARE, BY REGION, 2020 (%) 90

FIGURE 19 WESTERN EUROPE: NEUROPATHIC PAIN MARKET SHARE, BY COUNTRY, 2020 (%) 95

FIGURE 20 ASIA-PACIFIC: NEUROPATHIC PAIN MARKET SHARE, BY COUNTRY, 2020 (%) 129

FIGURE 21 MIDDLE EAST & AFRICA: NEUROPATHIC PAIN MARKET SHARE, BY REGION, 2020 (%) 159

FIGURE 22 BENCHMARKING OF MAJOR COMPETITORS 174

FIGURE 23 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN GLOBAL NEUROPATHIC PAIN MARKET 175

FIGURE 24 COMPETITIVE BENCHMARKING 176

FIGURE 25 SALES & OPERATING INCOME MARGIN, 2020 178

FIGURE 26 RESEARCH & DEVELOPMENT EXPENDITURE, 2020 178

FIGURE 27 ABBOTT: FINANCIAL OVERVIEW SNAPSHOT 180

FIGURE 28 ABBOTT: SWOT ANALYSIS 182

FIGURE 29 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT 183

FIGURE 30 PFIZER INC.: SWOT ANALYSIS 184

FIGURE 31 JOHNSON & JOHNSON SERVICES, INC.: FINANCIAL OVERVIEW SNAPSHOT 186

FIGURE 32 JOHNSON & JOHNSON SERVICES, INC.: SWOT ANALYSIS 187

FIGURE 33 BAXTER INTERNATIONAL INC.: FINANCIAL OVERVIEW 188

FIGURE 34 BAXTER INTERNATIONAL INC.: SWOT ANALYSIS 189

FIGURE 35 ELI LILY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT 191

FIGURE 36 ELI LILY AND COMPANY: SWOT ANALYSIS 192

FIGURE 37 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT 193

FIGURE 38 GLAXOSMITHKLINE PLC: SWOT ANALYSIS 194

FIGURE 39 SANOFI: FINANCIAL OVERVIEW SNAPSHOT 196

FIGURE 40 SANOFI: SWOT ANALYSIS 197

FIGURE 41 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT 198

FIGURE 42 ASTRAZENECA: SWOT ANALYSIS 199

FIGURE 43 DEPOMED, INC.: FINANCIAL OVERVIEW SNAPSHOT 200

FIGURE 44 DEPOMED, INC.: SWOT ANALYSIS 201

FIGURE 45 BIOGEN, INC.: FINANCIAL OVERVIEW SNAPSHOT 202

FIGURE 46 BIOGEN: SWOT ANALYSIS 203

FIGURE 47 ASTELLAS PHARMA LTD.: FINANCIAL OVERVIEW SNAPSHOT 204

FIGURE 48 ASTELLAS PHARMA: SWOT ANALYSIS 2051 EXECUTIVE SUMMARY